P2, N=4, Terminated, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Terminated; After careful consideration, our company has decided to revise the overall development strategy for IBI310 and discontinue further registration research for this project. Consequently, the ongoing screening process will be terminated, and this decisi
IBI310 monotherapy or in combination with sintilimab were well-tolerated without unanticipated AEs in pts with advanced melanoma. The data preliminarily demonstrate an antitumor activity of the combination therapy in previously treated advanced melanoma (acral and NCSD melanomas). Research Funding: Innovent Biologics, Inc.
over 4 years ago
Clinical • Combination therapy
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)